Market Research Life Sciences Market Research Pharmaceuticals Market Research Drug Discovery Market Research

Microscopic Polyangiitis - Epidemiology Forecast to 2030

Best Price Guarantee Length Publisher Published Date SKU
from $3,750 80 Pages DelveInsight May, 2021 DEL16642508
Best Price Guarantee
Price from $3,750
Length 80 Pages
Publisher DelveInsight
Published Date May, 2021
SKU DEL16642508

DelveInsight’s ‘Microscopic polyangiitis (MPA) —Epidemiology Forecast–2030’ report delivers an in-depth understanding of the MPA, historical and forecasted epidemiology as well as the MPA epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Microscopic polyangiitis (MPA) Disease Understanding

Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis is an autoimmune disease that causes swelling of the blood vessels. Several types of ANCA vasculitis exist due to numerous causes, so patients diagnosed with ANCA vasculitis may display varied symptoms. The ANCA-associated vasculitides (AAV) are three separate conditions, i.e., granulomatosis with polyangiitis (GPA; formerly known as Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg–Strauss syndrome [CSS]).

Microscopic polyangiitis (MPA) is a rare autoimmune condition that causes blood vessel inflammation (vasculitis), restricting blood flow and lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. The cause of MPA is unknown, and it is not a contagious condition that does not usually show genetic predisposition and is not a form of cancer. The immune system is thought to play a critical role in the development of MPA. It is believed that the immune system becomes overactive, but it still is not known that what causes this condition. MPA symptoms depend on which blood vessels are involved and what organs in the body are affected. The most common symptoms of MPA include kidney inflammation, weight loss, skin lesions, nerve damage, and fevers.

Continued in the report…..

Microscopic polyangiitis (MPA) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of MPA, Gender-Specific Incident Cases of MPA, and Age-Specific Incident Cases of MPA scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Microscopic polyangiitis (MPA) Detailed Epidemiology Segmentation
• In 2020, the total incident cases of MPA were found out to be 5,196 in the 7MM. As per the estimates by DelveInsight, these cases are expected to decrease at a CAGR of -0.02%, for the study period of 2018–2030. As the major contributor to the incident population are Japan (population growth rate, -0.4%) and Germany (population growth rate, -0.3%) where the population is declining, hence there is a decrease in the incident cases of MPA also.
• As per estimates, Japan had the highest incident cases of MPA (2,280), and among the EU5, Germany had the highest incident cases (1,041), followed by the UK (387), in 2020.
• In 2020, 660 incident cases were observed in the males, whereas 325 incident cases were observed in females in the US.

Scope of the Report
• The report covers the descriptive overview of MPA, explaining its causes, symptoms, pathogenesis, genetic basis, and diagnosis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of MPA.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of MPA, Gender-specific Incident Cases of MPA, and Age-specific Incident Cases of MPA.

Report Highlights
• 10-Year Forecast of MPA
• 7MM Coverage
• Total Incident Cases of MPA
• Gender-specific Incident Cases of MPA
• Age-specific Incident Cases of MPA.

Key Questions Answered
• What are the disease risk, and burdens of MPA?
• What is the historical MPA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of MPA at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MPA?
• Out of the above-mentioned countries, which country would have the highest incident population of MPA during the forecast period (2021–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The MPA report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM MPA epidemiology forecast.
• The MPA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The MPA epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030


1 Report Introduction
2 Executive Summary of Microscopic Polyangiitis (MPA)
3 Disease Background and Overview
3.1 Introduction
3.2 Causes
3.3 Symptoms of MPA
3.4 Clinical Manifestations of MPA
3.5 Pathogenesis of MPA
3.6 Biomarkers of MPA
3.7 Genetic Analysis
3.8 Diagnosis of MPA
3.8.1 Diagnostic Algorithm of Vasculitis
3.8.2 Diagnostic Guidelines of MPA
3.8.2.1 Revised 2017 International Consensus on Testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
3.8.2.2 EULAR/ERA-EDTA Recommendations for the Management of ANCA-associated Vasculitis
3.8.2.3 SICVE guidelines: Systemic vasculitis
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 Methodology of Epidemiology
4.3 Total Incident Cases of Microscopic polyangiitis (MPA) in the 7MM
4.4 Epidemiology of Microscopic polyangiitis (MPA)
4.5 The United States
4.5.1 Total Incident Cases of Microscopic polyangiitis (MPA) in the US
4.5.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the US
4.5.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the US
4.6 EU5
4.6.1 Germany
4.6.1.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany
4.6.1.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany
4.6.1.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany
4.6.2 France
4.6.2.1 Total Incident Cases of Microscopic polyangiitis (MPA) in France
4.6.2.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in France
4.6.2.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in France
4.6.3 Italy
4.6.3.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Italy
4.6.3.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy
4.6.3.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy
4.6.4 Spain
4.6.4.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Spain
4.6.4.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain
4.6.4.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain
4.6.5 The United Kingdom
4.6.5.1 Total Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom
4.6.5.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom
4.6.5.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom
4.7 Japan
4.7.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Japan
4.7.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan
4.7.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan
5 Patient Journey
6 Appendix
6.1 Report Methodology
7 DelveInsight Capabilities
8 Disclaimer
9 About DelveInsight
Table 1 Summary of MPA, Epidemiology and Key Events (2018–2030)
Table 2 Summary of biomarkers/potential biomarkers in AAV
Table 3 SICVE guidelines: Systemic vasculitis Recommendations
Table 4 Total Incident Cases of Microscopic polyangiitis (MPA) in the 7MM (2018–2030)
Table 5 Total Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018–2030)
Table 6 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018–2030)
Table 7 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018–2030)
Table 8 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018–2030)
Table 9 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018–2030)
Table 10 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018–2030)
Table 11 Total Incident Cases of Microscopic polyangiitis (MPA) in France (2018–2030)
Table 12 Gender-specific Total Incident Cases of Microscopic polyangiitis (MPA) in France (2018–2030)
Table 13 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in France (2018–2030)
Table 14 Total Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018–2030)
Table 15 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018–2030)
Table 16 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018–2030)
Table 17 Total Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018–2030)
Table 18 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018–2030)
Table 19 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018–2030)
Table 20 Total Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018–2030)
Table 21 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018–2030)
Table 22 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018–2030)
Table 23 Total Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018–2030)
Table 24 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018–2030)
Table 25 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018–2030)
Figure 1 Vasculitis
Figure 2 Microscopic polyangiitis (MPA)
Figure 3 Symptoms of Microscopic polyangiitis (MPA)
Figure 4 Five most common clinical manifestations of MPA
Figure 5 Pathogenesis of MPA
Figure 6 Diagnostic Algorithm for Vasculitis
Figure 7 Diagnostic algorithm of MPA
Figure 8 Total Incident Cases of Microscopic polyangiitis (MPA) in the 7MM (2018–2030)
Figure 9 Total Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018–2030)
Figure 10 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018–2030)
Figure 11 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018–2030)
Figure 11 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018–2030)
Figure 13 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018–2030)
Figure 14 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018–2030)
Figure 15 Total Incident Cases of Microscopic polyangiitis (MPA) in France (2018–2030)
Figure 16 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in France (2018–2030)
Figure 17 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in France (2018–2030)
Figure 18 Total Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018–2030)
Figure 19 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018–2030)
Figure 20 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018–2030)
Figure 21 Total Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018–2030)
Figure 22 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018–2030)
Figure 23 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018–2030)
Figure 24 Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018–2030)
Figure 25 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018–2030)
Figure 25 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018–2030)
Figure 27 Total Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018–2030)
Figure 28 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018–2030)
Figure 29 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018–2030)

$3,750
$11,250

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings